Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menveo booster immunogenicity and safety study in previously vaccinated and vaccine-naive healthy individuals
2016-003186-25Phase 3
- Sponsor
- GSK
- Start
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal A conjugate vaccine in meningococcal disease (4 arms), sponsored by GSK. Primary endpoints: Primary immunogenicity endpoint and Booster response adequacy.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2016-003186-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003186-25.